N-(1-Benzyl-piperidin-4-ylMethyl)-2-chloro-acetaMide
|
- $322 - $806
- Product name: N-(1-Benzyl-piperidin-4-ylMethyl)-2-chloro-acetaMide
- CAS: 1353952-74-5
- MF: C15H21ClN2O
- MW: 280.79
- EINECS:
- MDL Number:
- Synonyms:N-(1-Benzyl-piperidin-4-ylMethyl)-2-chloro-acetaMide;Acetamide, 2-chloro-N-[[1-(phenylmethyl)-4-piperidinyl]methyl]-
4 prices
Selected condition：
Brand
- Alichem
- Chemenu
- Crysdot
Package
- 250mg
- 1g
- ManufacturerAlichem
- Product number1353952745
- Product descriptionN-((1-Benzylpiperidin-4-yl)methyl)-2-chloroacetamide
- Packaging1g
- Price$707.41
- Updated2021-12-16
- Buy
- ManufacturerChemenu
- Product numberCM179961
- Product descriptionN-((1-Benzylpiperidin-4-yl)methyl)-2-chloroacetamide 95%
- Packaging1g
- Price$754
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11286420
- Product descriptionN-((1-Benzylpiperidin-4-yl)methyl)-2-chloroacetamide 95+%
- Packaging250mg
- Price$322
- Updated2021-12-16
- Buy
- ManufacturerCrysdot
- Product numberCD11286420
- Product descriptionN-((1-Benzylpiperidin-4-yl)methyl)-2-chloroacetamide 95+%
- Packaging1g
- Price$806
- Updated2021-12-16
- Buy
| Manufacturer | Product number | Product description | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|
| Alichem | 1353952745 | N-((1-Benzylpiperidin-4-yl)methyl)-2-chloroacetamide | 1g | $707.41 | 2021-12-16 | Buy |
| Chemenu | CM179961 | N-((1-Benzylpiperidin-4-yl)methyl)-2-chloroacetamide 95% | 1g | $754 | 2021-12-16 | Buy |
| Crysdot | CD11286420 | N-((1-Benzylpiperidin-4-yl)methyl)-2-chloroacetamide 95+% | 250mg | $322 | 2021-12-16 | Buy |
| Crysdot | CD11286420 | N-((1-Benzylpiperidin-4-yl)methyl)-2-chloroacetamide 95+% | 1g | $806 | 2021-12-16 | Buy |
Properties
Boiling point :440.2±25.0 °C(Predicted)
Density :1.135±0.06 g/cm3(Predicted)
pka :14.07±0.46(Predicted)
Density :1.135±0.06 g/cm3(Predicted)
pka :14.07±0.46(Predicted)
Safety Information
| Symbol(GHS): | ||||||||
|---|---|---|---|---|---|---|---|---|
| Signal word: | ||||||||
| Hazard statements: |
|
|||||||
| Precautionary statements: |
|